{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=6", "query": { "condition": "Solid Malignancy", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 5455, "total_pages": 546, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T04:24:00.310Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01988896", "title": "Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2013-12-27", "completion_date": "2019-11-04", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-23T04:24:00.310Z", "location_count": 11, "location_summary": "Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01988896" }, { "nct_id": "NCT06279013", "title": "Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Counseling", "type": "OTHER" }, { "name": "Health Education", "type": "BEHAVIORAL" }, { "name": "Interview", "type": "OTHER" }, { "name": "Medical Chart Review", "type": "OTHER" }, { "name": "Monitoring", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2024-10-14", "completion_date": "2032-05-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-23T04:24:00.310Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Albany, Georgia + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Albany", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06279013" }, { "nct_id": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Histiocytic Sarcoma", "Juvenile Xanthogranuloma", "Langerhans Cell Histiocytosis", "Malignant Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Recurrent Soft Tissue Sarcoma", "Refractory Ewing Sarcoma", "Refractory Glioma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Rhabdoid Tumor", "Stage III Osteosarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Osteosarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Osteosarcoma AJCC v7", "Stage IVB Osteosarcoma AJCC v7", "Wilms Tumor" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ensartinib", "type": "DRUG" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Samotolisib", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" }, { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Tipifarnib", "type": "DRUG" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 1377, "start_date": "2017-07-31", "completion_date": "2027-01-06", "has_results": true, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-23T04:24:00.310Z", "location_count": 168, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155620" }, { "nct_id": "NCT00509782", "title": "Phase I Trial of ZIO-101 in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ZIO-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 47, "start_date": "2005-05", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2012-08-01", "last_synced_at": "2026-10-23T04:24:00.310Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509782" }, { "nct_id": "NCT00891280", "title": "Dose-escalation Study of Oral CX-4945", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Breast Cancer", "Inflammatory Breast Cancer", "Castleman's Disease", "Multiple Myeloma" ], "interventions": [ { "name": "CX-4945 oral formulation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cylene Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2009-02", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2011-06-15", "last_synced_at": "2026-10-23T04:24:00.310Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Fort Collins, Colorado • Loveland, Colorado + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Loveland", "state": "Colorado" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00891280" }, { "nct_id": "NCT04570423", "title": "A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "Eflapegrastim", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Month to 17 Years" }, "enrollment_count": 40, "start_date": "2021-05-20", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-23T04:24:00.310Z", "location_count": 5, "location_summary": "Valhalla, New York • Charlotte, North Carolina • Cleveland, Ohio + 1 more", "locations": [ { "city": "Valhalla", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04570423" }, { "nct_id": "NCT07226180", "title": "Development and Application of Patient-Derived Models of Cancer", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Certis Oncology Solutions, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-12-11", "completion_date": "2029-09-30", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-23T04:24:00.310Z", "location_count": 3, "location_summary": "Irvine, California • Newport Beach, California", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226180" }, { "nct_id": "NCT02360215", "title": "Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cognitive Impairment", "Metastatic Malignant Neoplasm in the Brain", "Solid Neoplasm" ], "interventions": [ { "name": "Whole brain radiation therapy with hippocampal avoidance", "type": "RADIATION" }, { "name": "Memantine", "type": "DRUG" }, { "name": "Whole brain radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2015-07", "completion_date": "2019-08-26", "has_results": true, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-23T04:24:00.310Z", "location_count": 212, "location_summary": "Tuscaloosa, Alabama • Gilbert, Arizona • Tucson, Arizona + 172 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Carmichael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02360215" }, { "nct_id": "NCT03213691", "title": "Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma", "Recurrent Childhood Central Nervous System Neoplasm", "Recurrent Childhood Non-Hodgkin Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Neuroblastoma", "Refractory Malignant Solid Neoplasm", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Primary Central Nervous System Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 21, "start_date": "2017-10-30", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-02-05", "last_synced_at": "2026-10-23T04:24:00.310Z", "location_count": 108, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 84 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03213691" }, { "nct_id": "NCT02646319", "title": "Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced Malignant Neoplasm", "Cervical Squamous Cell Carcinoma", "Endometrial Carcinoma", "Malignant Uterine Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Solid Neoplasm", "Stage III Bladder Cancer", "Stage III Prostate Cancer", "Stage III Renal Cell Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Cervical Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Cervical Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Ovarian Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Renal Cell Cancer", "Stage IVA Bladder Cancer", "Stage IVA Cervical Cancer", "Stage IVB Bladder Cancer", "Stage IVB Cervical Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nanoparticle Albumin-Bound Rapamycin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2016-01", "completion_date": "2018-04-24", "has_results": false, "last_update_posted_date": "2019-06-06", "last_synced_at": "2026-10-23T04:24:00.310Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02646319" } ] }